신약 개발 서비스 시장 예측(2026-2032년)

The Drug Discovery Services Market is projected to grow by USD 31.90 billion at a CAGR of 10.59% by 2032.

Drug discovery services are increasingly central to how pharmaceutical, biotechnology, academic, and public health organizations identify, validate, optimize, and advance new therapeutic candidates. These services span target identification, assay development, high-throughput screening, hit-to-lead optimization, medicinal chemistry, structural biology, in vitro and in vivo pharmacology, ADME, toxicology, biomarker discovery, and early translational research. Demand is being shaped by the need to reduce attrition, improve reproducibility, accelerate timelines, and access specialized capabilities across complex modalities such as biologics, peptides, oligonucleotides, cell and gene therapies, radiopharmaceuticals, and targeted protein degraders. Scientifically, the sector is supported by decades of evidence showing that early-stage failures are often driven by insufficient target validation, poor pharmacokinetics, toxicity signals, and weak translational relevance. As a result, sponsors are prioritizing integrated drug discovery services that combine biology, chemistry, computational modeling, disease-relevant assays, and quality-controlled data generation. The executive priority is no longer simply outsourcing discrete tasks; it is building resilient discovery ecosystems that improve decision-making, shorten experimental learning cycles, and support more confident progression from discovery to preclinical development.

Transformative Shifts in the Drug Discovery Services Landscape

The drug discovery services landscape is undergoing transformative shifts driven by scientific complexity, regulatory expectations, digitalization, and the globalization of R&D networks. One major shift is the movement from linear outsourcing to integrated discovery partnerships, where multidisciplinary teams align around therapeutic hypotheses, target biology, chemistry strategy, and translational endpoints. Another shift is the growing use of disease-relevant models, including patient-derived cells, organoids, advanced co-culture systems, and humanized models, to improve biological relevance before clinical testing. Precision medicine is also reshaping discovery workflows by linking genomics, proteomics, metabolomics, phenotypic data, and biomarker strategies to patient segmentation earlier in the process. At the same time, regulatory science is encouraging stronger evidence packages for safety, mechanism of action, data integrity, and model justification. The adoption of automation, laboratory information management systems, electronic notebooks, and standardized data pipelines is improving reproducibility and auditability. These shifts are creating a more evidence-led service environment in which speed matters, but decision quality, traceability, and translational validity are increasingly decisive.

Cumulative Impact of Artificial Intelligence on Drug Discovery Services

Artificial intelligence is having a cumulative impact across drug discovery services by improving how organizations search chemical and biological space, prioritize targets, design molecules, interpret omics data, and plan experiments. AI-enabled methods are being applied to target identification, protein structure prediction, virtual screening, de novo molecular design, synthetic route planning, image-based phenotypic screening, toxicity prediction, and patient stratification. Peer-reviewed advances in structural prediction and machine learning-based molecular modeling have demonstrated practical value in hypothesis generation, while laboratory validation remains essential because computational predictions can be limited by biased datasets, incomplete biology, and poor transferability across disease contexts. The most effective AI adoption is therefore not a replacement for experimental discovery but a closed-loop model in which algorithms propose, laboratories test, and resulting data refine subsequent predictions. For service providers and sponsors, the strategic value of AI lies in reducing unproductive experimentation, identifying non-obvious patterns, improving compound prioritization, and enabling more disciplined portfolio decisions. Data governance, model transparency, secure data sharing, and rigorous validation are becoming critical differentiators as AI becomes embedded in discovery operations.

Key Regional Insights Across Global Drug Discovery Services

Asia-Pacific is strengthening its role in drug discovery services through expanding biotechnology clusters, government-supported biomedical innovation, high scientific output, and cost-competitive research infrastructure across major economies. The region benefits from large patient populations, growing clinical and translational research capabilities, and increasing investment in genomics, biologics, and precision medicine. North America remains a leading hub for advanced discovery science, supported by mature pharmaceutical and biotechnology ecosystems, strong academic research, venture financing, advanced laboratory infrastructure, and established regulatory pathways that emphasize data quality and safety. Latin America is gaining relevance through biodiversity-driven research, improving clinical research capacity, and expanding academic-industry collaboration, particularly in infectious disease, oncology, and metabolic disorders. Europe continues to emphasize high-quality biomedical research, regulatory rigor, cross-border scientific collaboration, and public-private innovation frameworks, with notable strength in translational medicine, biologics, rare diseases, and advanced therapeutic modalities. The Middle East is investing in biomedical research capacity, genomics programs, specialized healthcare infrastructure, and innovation zones that support long-term diversification into life sciences. Africa is increasingly important for infectious disease research, genomic surveillance, population health studies, and locally relevant therapeutic innovation, supported by expanding research networks and international collaborations. Across these regions, drug discovery services are being shaped by the need for scientific specialization, ethical research practices, robust data infrastructure, and regionally relevant disease insights.

Key Group Insights Shaping Drug Discovery Services

ASEAN is emerging as a collaborative life sciences region, supported by expanding biomedical research capacity, improving regulatory coordination, and growing interest in infectious disease, metabolic disease, oncology, and tropical medicine research. GCC countries are prioritizing healthcare transformation, genomic medicine, biotechnology investment, and research infrastructure as part of broader economic diversification strategies, creating opportunities for discovery partnerships linked to precision health and regional disease burdens. The European Union provides a highly structured environment for drug discovery services through harmonized regulatory frameworks, multinational research programs, strong academic networks, and an emphasis on data protection, ethics, and translational science. BRICS countries contribute scale, scientific talent, manufacturing linkages, diverse disease populations, and increasing public and private investment in biotechnology, making the group relevant for both discovery and downstream development integration. G7 economies remain influential due to advanced research institutions, mature intellectual property frameworks, high regulatory standards, and concentration of specialized expertise in biologics, computational discovery, advanced analytics, and complex therapeutic modalities. NATO member countries, while not a life sciences bloc, include many economies with strong biomedical research systems, secure data infrastructure priorities, and defense-linked interest in medical countermeasures, biodefense, infectious disease preparedness, and resilient pharmaceutical supply chains. Together, these groups shape drug discovery services through policy alignment, research funding, cross-border collaboration, regulatory expectations, and the development of secure, innovation-oriented ecosystems.

Key Country Insights in Drug Discovery Services

The United States is a major center for drug discovery services due to its dense network of biotechnology firms, academic medical centers, advanced laboratories, venture funding, and regulatory experience across small molecules, biologics, and advanced therapies. Canada contributes strong capabilities in academic research, artificial intelligence, biologics, immunology, neuroscience, and translational medicine, supported by collaborative public research systems. Mexico is building relevance through pharmaceutical manufacturing links, clinical research activity, and proximity to North American life sciences supply chains. Brazil offers scientific depth in biodiversity, infectious disease, oncology, and public health research, supported by established universities and biomedical institutes. The United Kingdom remains influential in genomics, structural biology, translational research, and early-stage biotechnology, supported by strong academic-industry linkages and health data resources. Germany brings strengths in medicinal chemistry, engineering, biologics, diagnostics, and high-quality laboratory infrastructure, while France contributes expertise in immunology, oncology, neuroscience, rare diseases, and public research networks. Russia has scientific capabilities in chemistry, virology, immunology, and vaccine-related research, though international collaboration dynamics and regulatory conditions influence engagement. Italy and Spain support drug discovery through strong academic medicine, oncology research, neuroscience, infectious disease studies, and participation in European research frameworks. China has expanded rapidly in biotechnology, medicinal chemistry, genomics, biologics, and AI-enabled research, supported by large-scale R&D investment and growing scientific publication output. India is a significant destination for chemistry services, biology support, informatics, generics-linked expertise, and increasingly integrated discovery capabilities, strengthened by a large scientific workforce. Japan remains highly advanced in pharmaceutical research, regenerative medicine, structural biology, and precision medicine, supported by rigorous scientific standards. Australia contributes through clinical translation, immunology, oncology, infectious disease research, and strong academic networks. South Korea is advancing in biologics, cell therapy, genomics, digital health, and translational biotechnology, supported by national innovation programs and sophisticated healthcare infrastructure.

Actionable Recommendations for Drug Discovery Services Leaders

Industry leaders should prioritize integrated discovery models that combine target biology, medicinal chemistry, translational pharmacology, computational science, and biomarker planning from the earliest stages. Building high-quality, interoperable data systems is essential for reproducibility, AI readiness, and defensible decision-making. Organizations should invest in disease-relevant models and human biology platforms to improve translational confidence before advancing candidates. AI should be deployed through validated, closed-loop workflows that pair predictive analytics with experimental confirmation rather than relying on algorithmic output alone. Sponsors should evaluate service partners based on scientific depth, data integrity, assay reproducibility, quality systems, intellectual property safeguards, regulatory awareness, and cross-functional communication. Diversifying regional discovery networks can improve access to specialized talent, disease-relevant biology, and operational resilience, but it requires strong governance and harmonized quality standards. Leaders should also strengthen early safety assessment, ADME optimization, and biomarker strategies to reduce downstream attrition. Finally, collaborative models involving academia, public institutions, clinical networks, and specialized service providers can improve access to novel targets, patient-derived data, and emerging therapeutic technologies.

Research Methodology for Drug Discovery Services Analysis

This executive summary is developed using a structured secondary research methodology focused on verified, publicly available, and data-backed sources. The research approach includes review of peer-reviewed biomedical literature, regulatory guidance, public health databases, patent and publication trends, clinical research registries, policy documents, academic research outputs, and internationally recognized life sciences reports. Findings are triangulated across scientific, regulatory, technological, and regional evidence to identify consistent patterns in drug discovery services without relying on market sizing, market share, or forecasting. The methodology emphasizes evidence quality, source credibility, relevance to discovery workflows, and consistency across geographies and therapeutic areas. Particular attention is given to target validation, translational model development, AI applications, assay reproducibility, safety assessment, biomarker integration, and regional R&D capacity. The analysis excludes promotional claims and avoids company-specific positioning, focusing instead on industry-level dynamics, scientific drivers, and actionable implications for decision-makers across pharmaceutical, biotechnology, academic, and public research ecosystems.

Conclusion: Advancing the Future of Drug Discovery Services

Drug discovery services are evolving into a strategic engine for scientific innovation, operational efficiency, and translational decision-making. The industry is being reshaped by integrated outsourcing, disease-relevant biology, precision medicine, automation, artificial intelligence, and growing regional specialization. While AI is accelerating hypothesis generation and data interpretation, experimentally validated science remains the foundation of credible discovery. Regional and country-level ecosystems are contributing distinct strengths, from advanced biomedical infrastructure and regulatory expertise to patient diversity, computational science, and emerging biotechnology capacity. For industry leaders, success will depend on selecting partners and operating models that strengthen data quality, biological relevance, safety insight, and cross-disciplinary integration. Organizations that combine rigorous science with digital readiness, ethical governance, and global collaboration will be best positioned to advance stronger therapeutic candidates and improve the productivity of early-stage drug development.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Drug Discovery Services Market, by Service Type

• 7.1. Introduction
• 7.2. Chemistry Services
  • 7.2.1. Medicinal Chemistry
  • 7.2.2. Synthetic Chemistry
  • 7.2.3. Peptide Synthesis
• 7.3. Biology Services
  • 7.3.1. Cell-based Assays
  • 7.3.2. Biochemical Assays
  • 7.3.3. Molecular Biology
  • 7.3.4. Microbiology Services
• 7.4. Drug Metabolism & Pharmacokinetics
  • 7.4.1. In Vitro ADME
  • 7.4.2. In Vivo Pharmacokinetics
  • 7.4.3. Bioanalysis
• 7.5. Pharmacology Services
• 7.6. Toxicology Services
  • 7.6.1. Acute Toxicity
  • 7.6.2. Chronic Toxicity
  • 7.6.3. Genotoxicity
• 7.7. DMPK Services
  • 7.7.1. Absorption Studies
  • 7.7.2. Distribution Studies
  • 7.7.3. Metabolism Studies
• 7.8. Biomarker Services

8. Drug Discovery Services Market, by Technology

• 8.1. Introduction
• 8.2. Computational Biology
  • 8.2.1. Bioinformatics
  • 8.2.2. Cheminformatics
  • 8.2.3. Molecular Modeling
• 8.3. Flow Cytometry
• 8.4. High Throughput Screening
  • 8.4.1. Biochemical Assays
  • 8.4.2. Cell Based Assays
  • 8.4.3. Label Free Assays
• 8.5. Mass Spectrometry
• 8.6. Nuclear Magnetic Resonance
• 8.7. X Ray Crystallography

9. Drug Discovery Services Market, by Drug Type

• 9.1. Introduction
• 9.2. Small Molecules
• 9.3. Biologics
  • 9.3.1. Monoclonal Antibodies
  • 9.3.2. Recombinant Proteins
  • 9.3.3. Vaccines
  • 9.3.4. Cell Therapies
  • 9.3.5. Gene Therapies

10. Drug Discovery Services Market, by Service Delivery Model

• 10.1. Introduction
• 10.2. In-house Services
• 10.3. Outsourced Services

11. Drug Discovery Services Market, by Therapeutic Area

• 11.1. Introduction
• 11.2. Cardiovascular Disorders
• 11.3. Neurology
  • 11.3.1. Neurodegenerative Disorders
  • 11.3.2. Psychiatric Disorders
• 11.4. Infectious Diseases
  • 11.4.1. Viral Diseases
  • 11.4.2. Bacterial Infections
• 11.5. Metabolic Disorders
  • 11.5.1. Diabetes
  • 11.5.2. Obesity
• 11.6. Oncology
• 11.7. Immunology
  • 11.7.1. Autoimmune Diseases
  • 11.7.2. Inflammatory Disorders
• 11.8. Respiratory Diseases
• 11.9. Gastrointestinal Diseases

12. Drug Discovery Services Market, by End User

• 12.1. Introduction
• 12.2. Academic & Research Institutes
• 12.3. Biotechnology Companies
• 12.4. Contract Research Organizations
• 12.5. Pharmaceutical Companies
• 12.6. Government Organizations

13. Drug Discovery Services Market, by Region

• 13.1. Asia-Pacific
• 13.2. Europe
• 13.3. North America
• 13.4. Latin America
• 13.5. Africa
• 13.6. Middle East

14. Drug Discovery Services Market, by Group

• 14.1. NATO
• 14.2. G7
• 14.3. BRICS
• 14.4. European Union
• 14.5. ASEAN
• 14.6. GCC

15. Drug Discovery Services Market, by Country

• 15.1. China
• 15.2. United States
• 15.3. Japan
• 15.4. India
• 15.5. Germany
• 15.6. United Kingdom
• 15.7. Australia
• 15.8. France
• 15.9. South Korea
• 15.10. Italy
• 15.11. Canada
• 15.12. Russia
• 15.13. Brazil
• 15.14. Mexico
• 15.15. Spain

16. Competitive Landscape

• 16.1. Market Share Analysis, 2025
• 16.2. FPNV Positioning Matrix, 2025
• 16.3. Market Concentration Analysis, 2025
  • 16.3.1. Concentration Ratio (CR)
  • 16.3.2. Herfindahl Hirschman Index (HHI)
• 16.4. Recent Developments & Impact Analysis, 2025
• 16.5. Product Portfolio Analysis, 2025
• 16.6. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Alloy Therapeutics, Inc.
• 17.2. Aragen Life Sciences Private Limited
• 17.3. BioAscent Discovery Ltd
• 17.4. Charles River Laboratories, Inc.
• 17.5. Charnwood Discovery Limited
• 17.6. Crown Bioscience, Inc.
• 17.7. Curia Global, Inc.
• 17.8. Domainex Limited
• 17.9. Edelris SAS
• 17.10. Enamine Ltd.
• 17.11. Eurofins Scientific SE
• 17.12. Evotec SE
• 17.13. Medicilon Inc.
• 17.14. Metrion Biosciences Limited
• 17.15. Oncodesign Services S.A.S.
• 17.16. Pelago Bioscience AB
• 17.17. Pharmaron Beijing Co., Ltd.
• 17.18. Proteros biostructures GmbH
• 17.19. Reaction Biology Corp.
• 17.20. Sai Life Sciences Limited
• 17.21. Selvita S.A.
• 17.22. SpiroChem AG
• 17.23. Sygnature Discovery Limited
• 17.24. Symeres B.V.
• 17.25. Syngene International Limited
• 17.26. TCG Lifesciences Private Limited
• 17.27. Viva Biotech Holdings
• 17.28. WuXi AppTec Co., Ltd.
• 17.29. X-Chem, Inc.